Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences, Inc. (NASDAQ: CSTL) will present company overviews at multiple investor conferences this November. These include the Credit Suisse 31st Annual Healthcare Conference on Nov. 9, 2022, at 12:50 p.m. ET, the Stephens Annual Investment Conference on Nov. 16, 2022, at 11:00 a.m. ET, and the Canaccord Genuity MedTech Conference on Nov. 17, 2022, at 11:30 a.m. ET. Live webcasts will be accessible on their website, with replays available post-event.
Castle focuses on diagnostics, offering tests for skin cancers and other diseases.
Castle Biosciences (CSTL) announced the publication of clinical utility data in Cancer Investigation, revealing that clinicians are effectively using the DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma (SCC) patients. In the study, 98.1% of 2,503 samples were tested, with 68.8% classified as low-risk. The study reinforces the importance of risk assessment beyond traditional methods, as 75% of samples had multiple high-risk factors. Results indicate that the test aids in aligning treatment plans with patients' metastatic risks, potentially reducing overtreatment.
Castle Biosciences (CSTL) announced new data demonstrating the effectiveness of DecisionDx-Melanoma and DecisionDx-UM in accurately predicting the risk of death associated with melanoma in real-world patients. In collaboration with the National Cancer Institute, the studies showed that these tests can help identify low-risk patients who may avoid unnecessary therapies. The findings highlight potential healthcare cost reductions and improved treatment decisions, as evidenced by significant survival rate differences based on test results.
Castle Biosciences, Inc. (NASDAQ: CSTL) announced at the 2022 ACG Annual Scientific Meeting that its TissueCypher® Barrett's Esophagus Test significantly enhances management decisions for patients with low-grade dysplasia (LGD). The study showed that utilizing TissueCypher results led to a 58.4% likelihood of patients receiving appropriate management compared to 9.1% with standard care. This test aims to standardize care, reduce unnecessary therapies, and potentially lower esophageal cancer risks. The findings suggest a substantial impact on patient outcomes.
Castle Biosciences (NASDAQ: CSTL) announced positive results from its UTILISE study on DecisionDx-SCC, a test for managing cutaneous squamous cell carcinoma (cSCC). The data, shared at the 2022 Fall Clinical Dermatology Conference, indicates that over 80% of patients experienced favorable changes in management based on test results. Specifically, 42% of clinicians noted the test was the most influential factor in patient management, with 59% expressing increased confidence in treatment plans. This study aligns with prior findings on the test's clinical utility and risk stratification effectiveness.
Castle Biosciences, Inc. (NASDAQ: CSTL) announced significant findings from its DECIDE study at the 19th International Congress of the Society for Melanoma Research. The study reveals that DecisionDx-Melanoma test results influenced 85% of clinicians' decisions regarding sentinel lymph node biopsy (SLNB) procedures. Notably, the test associated with a 29% reduction in SLNBs for low-risk patients. The data emphasizes the test's role in guiding risk-aligned patient care, allowing patients with low biological risk to safely forgo SLNB, potentially avoiding unnecessary complications.
Castle Biosciences, Inc. (CSTL) will release its financial results for Q3 and the nine months ended Sept. 30, 2022, after market close on Nov. 2, 2022. The company will host a conference call at 4:30 p.m. Eastern time on the same day to discuss these results. Castle Biosciences focuses on innovative tests that guide patient care and has a portfolio that includes diagnostics for skin cancers and other conditions, with ongoing R&D for new tests targeting high clinical needs.
Castle Biosciences (CSTL) presented new data at the 30th United European Gastroenterology Week in Vienna, showing that its TissueCypher Barrett’s Esophagus Test significantly improves physician accuracy in assessing the risk of high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus. Participants using TissueCypher were 65.6% more likely to predict progression to HGD or EAC, and adherence to management guidelines improved. The test is supported by multiple peer-reviewed publications and is critical for enhancing patient care and treatment strategies.
Castle Biosciences (Nasdaq: CSTL) presented a poster at the CAP22 Annual Meeting showcasing its DiffDx-Melanoma test, which demonstrated over 98% accuracy in diagnosing melanocytic lesions. The test supports decisions for local excision in challenging cases where traditional methods are inconclusive. The company’s gene expression profile tests aim to aid dermatologists in providing confident treatment plans for approximately 300,000 ambiguous lesions annually in the U.S. Detailed case study results are available in the presented poster.
Castle Biosciences, Inc. (NASDAQ: CSTL) presented impactful data at the 2022 ASDS Annual Meeting, showcasing its DecisionDx®-SCC test for cutaneous squamous cell carcinoma (SCC). This 40-gene expression profile test helps predict metastasis risk, enabling better patient management. Notably, 42% of Mohs surgeons reported increased confidence in their treatment decisions when using the test. The study revealed that familiarity with DecisionDx-SCC was high among clinicians (97%), emphasizing its role in guiding risk-aligned management strategies.